Kirkland Advises Bristol Myers Squibb on €5 Billion Senior Notes Offering and $7.5 Billion Tender Offer for Outstanding Notes
Kirkland & Ellis advised Bristol Myers Squibb (NYSE: BMY), a global pharmaceutical company, on its inaugural €5 billion public offering of senior unsecured notes using a finance subsidiary structure and on its concurrent tender offer of over $7.5 billion to purchase various series of its outstanding notes. The notes were issued by Bristol Myers Squibb’s wholly owned subsidiary, BMS Ireland Capital Funding Designated Activity Company, and are fully and unconditionally guaranteed by Bristol Myers Squibb. The notes offering closed on November 10, 2025, and the tender offer settled on November 20, 2025.
Read the transaction press releases here and here
The Kirkland team included capital markets lawyers Sophia Hudson, Asher Qazi, Parker Davis, Lune Klappe-Regan, Richard Hong, Saud Alshaikh and Basit Khan Bangash; tax lawyers Sara Zablotney, Vivek Ratnam, Yewande Ford and Margot Solmssen; and investment funds regulatory lawyer Phil Giglio.
